menu
    • menu

    Company profile for Tizona Therapeutics

    NEW Drugs in Dev: 1
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Tizona develops next-generation immunotherapies The successful development of immunotherapies represents one of the most important and exciting breakthroughs in cancer. Recent approvals of checkpoint inhibitors provide evidence that the immune system is capable of recognizing cancerous cells and eradicating them. These checkpoint inhibitors can achieve complete, durable remissions and help patients live longer. Yet, despite t...
    Tizona develops next-generation immunotherapies The successful development of immunotherapies represents one of the most important and exciting breakthroughs in cancer. Recent approvals of checkpoint inhibitors provide evidence that the immune system is capable of recognizing cancerous cells and eradicating them. These checkpoint inhibitors can achieve complete, durable remissions and help patients live longer. Yet, despite this progress, existing immunotherapies are effective in a relatively small number of patients and types of cancer.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Tizona TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    4000 Shoreline Court, Suite 200 South San Francisco, CA 94080
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    --
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Tizona Therapeutics Shows Dual Immune Activation With TTX-080
    Tizona Therapeutics Shows Dual Immune Activation With TTX-080

    07 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/07/3183672/0/en/Tizona-Therapeutics-Presents-Clinical-Translational-Evidence-of-Dual-Innate-and-Adaptive-Immune-Activation-with-TTX-080-a-First-in-Class-HLA-G-Antagonist-in-Patients-with-Advanced-.html

    GLOBENEWSWIRE
    07 Nov 2025
    Share Share
    Tizona Therapeutics Expands Phase 1b Trial for Colorectal Cancer
    Tizona Therapeutics Expands Phase 1b Trial for Colorectal Cancer

    31 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/31/2972639/0/en/Tizona-Therapeutics-Announces-Expansion-of-Phase-1b-Clinical-Trial-to-Evaluate-TTX-080-in-Combination-with-EGFR-Inhibitor-Cetuximab-and-Chemotherapy-in-Advanced-Colorectal-Cancer.html

    GLOBENEWSWIRE
    31 Oct 2024
    Share Share
    Tizona Ttx-080 Phase 1b Data: Crc And Hnscc At Asco 2024
    Tizona Ttx-080 Phase 1b Data: Crc And Hnscc At Asco 2024

    23 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/23/2887689/0/en/Tizona-Therapeutics-Presents-Phase-1b-TTX-080-Clinical-Data-in-Advanced-Colorectal-Cancer-and-Head-and-Neck-Squamous-Cell-Carcinoma-at-ASCO-2024.html

    GLOBENEWSWIRE
    23 May 2024
    Share Share
    Gilead backs out of option to buy immunotherapy-focused Tizona
    Gilead backs out of option to buy immunotherapy-focused Tizona

    06 Feb 2024

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/gilead-will-not-buy-tizona-after-paying-300m-right-do-so

    FIERCE BIOTECH
    06 Feb 2024
    Share Share
    Gilead passes on fully acquiring Pionyr, as eyes now turn to Tizona
    Gilead passes on fully acquiring Pionyr, as eyes now turn to Tizona

    23 Mar 2023

    // Kyle LaHucik ENDPTS

    https://endpts.com/gilead-passes-on-fully-acquiring-pionyr-as-eyes-now-turn-to-tizona-a-fellow-summer-2020-buyout-option/

    Kyle LaHucik ENDPTS
    23 Mar 2023
    Share Share
    Tizona Begins Phase 1b Expansion Study of TTX-080 in Advanced r/r Malignancies
    Tizona Begins Phase 1b Expansion Study of TTX-080 in Advanced r/r Malignancies

    14 Oct 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211014005093/en

    BUSINESSWIRE
    14 Oct 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search